Abstract: A thermal treatment system with acoustic monitoring applies substantially constant electromagnetic energy superposed with pulsed electromagnetic energy to targeted tissue. The pulsed electromagnetic energy reacts with tissue to create an acoustic pressure wave within the tissue. The acoustic pressure wave is sensed by an acoustic sensor, and a sensor signal indicative of the acoustic pressure wave is generated and processed to determine changes in tissue composition.
Abstract: The present invention provides a method for determining whether or not a cancer subject is suitable for treatment with a purine-based roscovitine-like inhibitor, which method comprises the step of determining the ras status of the cancer, wherein a determination that the subject has mutant ras status is indicative that the subject is suitable for treatment with a purine-based roscovitine-like inhibitor.
Type:
Application
Filed:
December 21, 2011
Publication date:
January 3, 2013
Applicants:
Cyclacel Limited, The General Hospital Corporation d/b/a Massachusetts General Hospital, The Trustees of Dartmouth College
Inventors:
Simon Richard GREEN, Judy H. CHIAO, Jeffery SETTLEMAN, Ethan DMITROVSKY, Fabrizio Vittorio GALIMBERTI
Abstract: One aspect of the present invention is a method of playing multi-media content through a personal computer. The personal computer includes a processor and memory, with the memory having software instructions stored therein. The processor executes the instructions to carry-out the method. The method includes: receiving data representing multi-media content at the personal computer; receiving at the personal computer an initial set of data representing a base set of usage rights that is associated with the multi-media content, wherein the initial set of data defines a first set of rights that is permissible without upgrading or renewing the base set of usage rights; and upon receiving a request to perform an action involving the multi-media content, checking the initial set of data representing the base set of usage rights to determine whether the action is permissible, and providing an option to a user through the personal computer to contact a remote computer to negotiate for an upgraded set of usage rights.
Abstract: The present invention embraces a bi-specific fusion protein composed of an effector cell-specific antibody-variable region fragment operably linked to at least a portion of a natural killer cell receptor. Methods for using the fusion protein in the treatment of cancer and pathogenic infections are also provided.
Abstract: The present invention features monocyclic cyanoenone compositions and methods for using the same in the treatment of diseases such as cancer, inflammatory diseases and neurodegenerative diseases.
Abstract: A multi-mode to single mode optical interface device includes an optically pumped edge emitting semiconductor laser device and a lens. The optically pumped edge emitting semiconductor laser device includes (1) a gain area, and (2) an edge located single mode output. The lens focuses a multi-mode optical fiber output beam into a substantially line shaped output beam focused onto the gain area of the optically pumped edge emitting semiconductor laser device. A method for converting a multi-mode optical signal into a single mode optical signal includes (1) focusing the multi-mode optical signal onto a gain area of an optically pumped edge emitting semiconductor laser using at least a line focusing lens, and (2) converting the multi-mode optical signal into the single mode optical signal using the semiconductor laser.
Abstract: The present invention features methods for decreasing fat mass, increasing energy expenditure, increasing resistance to obesity, and lowering blood glucose levels in a subject with an agent that inhibits the expression or activity of type III deiodinase. In this regard, agents of the invention are useful in treating diabetes and obesity.
Type:
Grant
Filed:
September 1, 2009
Date of Patent:
November 6, 2012
Assignee:
Trustees of Dartmouth College
Inventors:
Donald L. St. Germain, Arturo Hernandez
Abstract: The present invention embraces microRNA-antagonists and activators of homeobox D10 protein; Zinc finger, MYND domain containing 11 protein; or RB1-inducible coiled-coil 1 protein for use in decreasing glial tumor cell proliferation and treating glioma.
Abstract: The present invention concerns methods for stimulating the growth and repair of bone and cartilage using synthetic triterpenoids and tricyclic-bis-enones. Examples of suitable triterpenoids include CDDO, CDDO-Me, CDDO-Im, and CDDO-Ethylamide. Examples of tricyclic-bis-enones include TBE-31 and TBE-34.
Type:
Grant
Filed:
November 16, 2007
Date of Patent:
October 30, 2012
Assignees:
Trustees of Dartmouth College, Osteoscreen, Inc., The Regents of the Universtiy of California
Inventors:
Michael B. Sporn, Karen T. Liby, Tadashi Honda, Gregory Mundy, Ross Garrett, Hari Reddi, Gordon W. Gribble, Takahiro Niikura
Abstract: Uracil auxotroph mutants of apicomplexans are provided which lack a functional carbamoyl phosphate synthase II (CPSII) enzyme. Also provided are T. gondii autoxtroph mutants which express exogenous antigens, and methods of protecting an animal against a T. gondii and non-T. gondii disease.
Abstract: The present invention provides attenuated Toxoplasma gondii knockout mutants of the de novo pyrimidine synthesis pathway and use of the same in vaccines and methods of providing an immune response and protecting a subject against infection by T. gondii and a non-T. gondii disease.
Abstract: Compositions and methods of using compositions that induce UBE1L or a ubiquitin-like protein ISG15, or inhibit a deconjugase UBP43 to degrade oncogenic proteins and enhance apoptosis of cancer (neoplastic) or pre-cancerous (pre-neoplastic) cells are provided. Methods for the prevention or treatment of cancer via administration of these compositions are also provided.
Type:
Grant
Filed:
October 31, 2008
Date of Patent:
October 9, 2012
Assignee:
Trustees of Dartmouth College
Inventors:
Ethan Dmitrovsky, Bret A. Hassel, Sutisak Kitareewan, Ian Pitha-Rowe
Abstract: The present invention relates to isolated nicotinamide riboside kinase (Nrk) nucleic acid sequences, vectors and cultured cells containing the same, and Nrk polypeptides encoded thereby. Methods for identifying individuals or tumors susceptible to nicotinamide riboside-related prodrug treatment and methods for treating cancer by administering an Nrk nucleic acid sequence or polypeptide in combination with a nicotinamide riboside-related prodrug are also provided. The present invention further provides screening methods for isolating a nicotinamide riboside-related prodrug and identifying a natural source of nicotinamide riboside.
Abstract: Compositions and methods for regulating CD154 gene expression are provided that rely on the interaction of hnRNP L with the CA-dinucleotide rich sequence of the 3?-untranslated region of CD154.
Abstract: The present invention relates to the constitutive activity of the Hedgehog pathway in non-small cell lung carcinoma (NSCLC). A method for diagnosing NSCLC by detecting the level of a component of the Hedgehog pathway is provided, as is a method for identifying subjects that will respond positively to treatment with a Hedgehog pathway antagonist. Methods for treating subjects with cancer or cancers resistant to Hedgehog pathway antagonists are also provided.
Type:
Grant
Filed:
August 14, 2006
Date of Patent:
September 25, 2012
Assignee:
Trustees of Dartmouth College
Inventors:
David J. Robbins, Ziqiang Yuan, John A. Goetz
Abstract: The present invention relates to a method of detecting cardiac ischemia by measuring the levels of BNP or NTproBNP. Increases in BNP or NTproBNP levels in an individual are indicative of cardiac ischemia.
Abstract: The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.
Abstract: The present invention is an inhibitor of the trypsin-like ?2/?2i sites of the proteasome. The inhibitor is characterized as being a peptide-based epoxyketone or vinyl sulfone that contains an arginine or 4-aminomethylene-L-phenylalanine at the C-terminus (i.e., at the P1 position). Methods for using the inhibitor to inhibit the activity of the ?2/?2i site of a proteasome and treat a proteasome-mediated disease or condition are also described.
Type:
Application
Filed:
February 17, 2012
Publication date:
August 23, 2012
Applicant:
Trustees of Dartmouth College
Inventors:
Alexei Kisselev, Dmitry V. Filippov, Herman Overkleeft
Abstract: A method for providing patient registration without fiducials comprises the steps of: spatially placing an ultrasound image of a patient randomly at different starting positions relative to a preoperative image; creating an independent registration corresponding to each different starting positions, by optimizing a spatial transformation between the preoperative image and the ultrasound image to provide a first batch of registrations; executing a second registration to fine-tune the alignment between the preoperative image and the ultrasound image; and concatenating the spatial transformation to obtain spatial transformation between the patient in an operating room and a corresponding preoperative image.
Type:
Application
Filed:
August 27, 2010
Publication date:
August 23, 2012
Applicant:
Dartmouth College
Inventors:
Songbai Ji, David W. Roberts, Alex Hartov, Keith D. Paulsen
Abstract: The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates ?CD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon ?CD3/?GITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed.
Type:
Grant
Filed:
April 24, 2006
Date of Patent:
August 7, 2012
Assignee:
Trustees of Dartmouth College
Inventors:
Randolph J. Noelle, Li-Fan Lu, Sergio Quezada, David Gondek